Clinical Trial Update: Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus [Phase 1, Phase 2]

View source ↗

Summary

This update covers the completion of a dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of REMD-477 in subjects…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes
• Type 2 Diabetes Mellitus

Drugs mentioned

• REMD-477

Snippet

Sponsor: REMD Biotherapeutics, Inc. | Conditions: Type 2 Diabetes Mellitus, Diabetes | Phase 1, Phase 2 | Status: COMPLETED